KLOW peptide stack ingredients
Two tripeptides, a longer synthetic chain and a fragment of a much larger protein.
The blend
KPV, GHK-Cu, BPC-157 and TB-500 are co-formulated under the KLOW name. They retain their separate chemical identities. The 80 mg composition describes their amounts by mass; it gives no measure of how much each contributes to a biological effect.
I hesitate over “largest ingredient.” It sounds as though it ought to mean “largest contribution,” yet the formulation has never been tested in a comparison that could establish such a ranking.
KPV
KPV is Lys-Pro-Val, the final tripeptide of alpha-melanocyte-stimulating hormone, usually shortened to alpha-MSH. Its molecular weight is 342.44 Da and its CAS identifier is 67727-97-3. The commonly listed KLOW formulation contains 10 mg.
The intestinal-cell and mouse-colitis study ties KPV to PepT1-mediated uptake and suppression of inflammatory signaling. The experimental surroundings matter: these findings involve gut epithelial and immune cells in vitro and oral delivery in mice. They give the small peptide a much more specific identity than the loose phrase “inflammation control.”
There is also chemical work modifying KPV at its lysine residue. Glycoalkylated analogs were synthesized and characterized to explore altered physical and chemical properties. Those modified molecules add to the formulation research; the study supplies no clinical result for KLOW.
GHK-Cu
GHK-Cu couples Gly-His-Lys to copper(II). It has a molecular weight of 402.92 Da and CAS identifier 89030-95-5. At 50 mg in the commonly listed formulation, it accounts for 62.5% of the total mass.
Loren Pickart first isolated GHK from human plasma in 1973; this history appears in the skin-regeneration review. That review also describes collagen and other connective-tissue findings, together with topical human cosmetic studies. Copper is relevant to lysyl oxidase, an enzyme that helps crosslink collagen and elastin.
A small peptide carrying a metal ion is satisfyingly concrete chemistry. It also makes copper-handling disorders a sensible subject for the safety discussion. The topical record and the gene-expression work are different kinds of evidence; neither establishes an injectable KLOW outcome.
BPC-157
BPC-157 is a synthetic chain of 15 amino acids derived from a partial sequence of a protein identified in human gastric juice. Its sequence is GEPPPGKPADDAGLV; its molecular weight is 1419.53 Da and its CAS identifier is 137525-51-0. The typical KLOW formulation assigns it 10 mg.
The rat Achilles tendon experiment is a substantial repair finding within that animal model. Later preclinical reviews discuss much broader activity. A 2025 intravenous safety pilot reported no observed adverse events in two healthy adults, with no measurable changes in the reported safety biomarkers. The pilot assessed a very small human sample and supplies no efficacy result for the blend.
I like how far the tendon question travels from the stomach-derived sequence. The practical clinical questions remain larger than that pilot can answer.
TB-500
TB-500 is Ac-LKKTETQ, an N-acetylated heptapeptide corresponding to the actin-binding region of thymosin beta-4. Its molecular weight is 889.02 Da, and its commonly listed KLOW share is 10 mg. The native protein contains 43 amino acids; the fragment contains seven.
The foundational rat wound experiment used the full-length protein.
The wound-healing results most often invoked here were obtained with thymosin beta-4. This parent protein binds actin, part of the machinery cells use for movement and structure. The presence of an actin-binding motif in a shorter molecule leaves many questions about the shorter molecule's behavior open.
To my mind, molecular identity is the least negotiable detail in this collection. A result obtained with the full protein has to retain that protein's name. TB-500/thymosin beta-4 is also prohibited at all times under WADA's S2 category, as discussed with the other status and safety concerns.
